| Primary |
| Dialysis |
36.4% |
| Renal Failure Chronic |
30.1% |
| Product Used For Unknown Indication |
8.1% |
| Anaemia |
8.1% |
| Hyperparathyroidism Secondary |
3.5% |
| Nephrogenic Anaemia |
3.3% |
| Drug Use For Unknown Indication |
2.6% |
| Anaemia Of Malignant Disease |
1.2% |
| Pre-existing Disease |
1.1% |
| Myelodysplastic Syndrome |
1.0% |
| Renal Failure |
0.7% |
| Hepatitis C |
0.6% |
| Haemodialysis |
0.5% |
| Peritoneal Dialysis |
0.5% |
| Hypertension |
0.4% |
| Renal Transplant |
0.4% |
| Pain |
0.4% |
| Pseudomonas Infection |
0.4% |
| Staphylococcal Infection |
0.4% |
| Anaemia Of Chronic Disease |
0.3% |
|
| Therapeutic Response Decreased |
39.1% |
| Haemoglobin Decreased |
10.6% |
| Aplasia Pure Red Cell |
7.1% |
| Drug Ineffective |
5.2% |
| Medication Error |
5.2% |
| Anaemia |
4.3% |
| Hospitalisation |
3.5% |
| Thrombocytopenia |
3.2% |
| Vomiting |
2.9% |
| Injection Site Pain |
2.6% |
| Death |
2.2% |
| Rash |
2.2% |
| Pyrexia |
2.1% |
| Pruritus |
1.9% |
| White Blood Cell Count Decreased |
1.8% |
| Haemoglobin Abnormal |
1.6% |
| Haemoglobin Increased |
1.3% |
| Nausea |
1.2% |
| Hypersensitivity |
1.1% |
| Sepsis |
1.1% |
|
| Secondary |
| Renal Failure Chronic |
18.6% |
| Dialysis |
13.0% |
| Product Used For Unknown Indication |
10.5% |
| Nephrogenic Anaemia |
9.3% |
| Anaemia |
9.2% |
| Hyperparathyroidism Secondary |
4.6% |
| Pseudomonas Infection |
4.6% |
| Staphylococcal Infection |
4.6% |
| Iron Deficiency Anaemia |
3.6% |
| Drug Use For Unknown Indication |
3.5% |
| Hepatitis C |
3.3% |
| Pain |
2.4% |
| Nausea |
2.2% |
| Hypertension |
1.9% |
| Renal Failure |
1.9% |
| Diabetes Mellitus |
1.5% |
| Peritoneal Dialysis |
1.5% |
| Haemodialysis |
1.4% |
| Anaemia Of Malignant Disease |
1.4% |
| Atrial Fibrillation |
1.2% |
|
| Therapeutic Response Decreased |
22.3% |
| Drug Ineffective |
15.0% |
| Aplasia Pure Red Cell |
12.1% |
| Haemoglobin Decreased |
9.1% |
| Staphylococcal Infection |
5.2% |
| Anaemia |
5.0% |
| White Blood Cell Count Decreased |
4.3% |
| Renal Failure |
3.4% |
| Vomiting |
3.4% |
| Rash |
2.3% |
| Viral Infection |
2.1% |
| Dyspnoea |
1.8% |
| Fatigue |
1.8% |
| Hypertension |
1.8% |
| Myalgia |
1.8% |
| Occult Blood Positive |
1.8% |
| Transplant Failure |
1.8% |
| Hernia |
1.6% |
| Multiple Myeloma |
1.6% |
| Oesophagitis |
1.6% |
|
| Concomitant |
| Drug Use For Unknown Indication |
34.6% |
| Product Used For Unknown Indication |
27.1% |
| Nuclear Magnetic Resonance Imaging |
8.8% |
| Angiogram |
3.4% |
| Peritoneal Dialysis |
3.3% |
| Multiple Myeloma |
3.1% |
| Hypertension |
2.9% |
| Anaemia |
2.4% |
| Nuclear Magnetic Resonance Imaging Brain |
2.1% |
| Pain |
2.0% |
| Prophylaxis |
1.5% |
| Supplementation Therapy |
1.2% |
| Imaging Procedure |
1.0% |
| Nuclear Magnetic Resonance Imaging Abdominal |
1.0% |
| Depression |
1.0% |
| Diabetes Mellitus |
1.0% |
| Renal Failure Chronic |
1.0% |
| Thrombosis Prophylaxis |
0.9% |
| Prophylaxis Against Transplant Rejection |
0.9% |
| Hyperparathyroidism Secondary |
0.9% |
|
| Vomiting |
21.1% |
| Skin Tightness |
10.6% |
| Nephrogenic Systemic Fibrosis |
8.8% |
| Weight Decreased |
8.6% |
| Subcutaneous Nodule |
7.5% |
| Peritonitis Bacterial |
4.9% |
| Skin Induration |
4.4% |
| Sepsis |
3.9% |
| Thrombocytopenia |
3.1% |
| Death |
2.9% |
| Pyrexia |
2.8% |
| Urinary Tract Infection |
2.7% |
| Myocardial Infarction |
2.5% |
| Peritonitis |
2.4% |
| White Blood Cell Count Increased |
2.4% |
| Renal Failure Chronic |
2.4% |
| Skin Ulcer |
2.3% |
| Unresponsive To Stimuli |
2.3% |
| Nephrogenic Fibrosing Dermopathy |
2.1% |
| Pain |
2.1% |
|
| Interacting |
| Product Used For Unknown Indication |
100.0% |
|
|
